AstraZeneca PLC – Analyzing the Stock Performance

Shares of AstraZeneca PLC have moved -4.5% today, and are now trading at a price of $63.57. In contrast, the S&P 500 index saw a 0.0% change. Today's trading volume is 25,225,679 compared to the stock's average volume of 5,509,188.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. Based in Cambridge, United Kingdom the company has 83,500 full time employees and a market cap of $197,091,147,776. AstraZeneca PLC currently offers its equity investors a dividend that yields 4.4% per year.

The company is now trading -22.34% away from its average analyst target price of $81.86 per share. The 10 analysts following the stock have set target prices ranging from $70.0 to $88.0, and on average give AstraZeneca PLC a rating of buy.

Over the last 12 months AZN shares have declined by -1.3%, which represents a difference of -23.7% when compared to the S&P 500. The stock's 52 week high is $76.56 per share and its 52 week low is $61.7. Based on AstraZeneca PLC's average net margin growth of 10.0% over the last 5 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023 11,416,000 1,820,000 16 128.57
2022 44,351,000 3,293,000 7 -46.15
2021 876,000 112,000 13 8.33
2020 26,617,000 3,144,000 12 140.0
2019 24,384,000 1,227,000 5 -44.44
2018 22,090,000 2,050,000 9
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.